Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

TREM-1 expression on neutrophils and monocytes of septic patients: relation to the underlying infection and the implicated pathogen

  • 1Email author,
  • 1,
  • 1,
  • 2,
  • 1,
  • 3,
  • 4,
  • 2,
  • 5,
  • 1,
  • 6,
  • 7,
  • 8,
  • 2,
  • 2,
  • 9,
  • 10,
  • 11,
  • 2 and
BMC Infectious Diseases201111:309

https://doi.org/10.1186/1471-2334-11-309

©  Poukoulidou et al; licensee BioMed Central Ltd. 2011

  • Received: 6 May 2011
  • Accepted: 4 November 2011
  • Published:
Open Peer Review reports

Abstract

Background

Current knowledge on the exact ligand causing expression of TREM-1 on neutrophils and monocytes is limited. The present study aimed at the role of underlying infection and of the causative pathogen in the expression of TREM-1 in sepsis.

Methods

Peripheral venous blood was sampled from 125 patients with sepsis and 88 with severe sepsis/septic shock. The causative pathogen was isolated in 91 patients. Patients were suffering from acute pyelonephritis, community-acquired pneumonia (CAP), intra-abdominal infections (IAIs), primary bacteremia and ventilator-associated pneumonia or hospital-acquired pneumonia (VAP/HAP). Blood monocytes and neutrophils were isolated. Flow cytometry was used to estimate the TREM-1 expression from septic patients.

Results

Within patients bearing intrabdominal infections, expression of TREM-1 was significantly lower on neutrophils and on monocytes at severe sepsis/shock than at sepsis. That was also the case for severe sepsis/shock developed in the field of VAP/HAP. Among patients who suffered infections by Gram-negative community-acquired pathogens or among patients who suffered polymicrobial infections, expression of TREM-1 on monocytes was significantly lower at the stage of severe sepsis/shock than at the stage of sepsis.

Conclusions

Decrease of the expression of TREM-1 on the membrane of monocytes and neutrophils upon transition from sepsis to severe sepsis/septic shock depends on the underlying type of infection and the causative pathogen.

Keywords

  • Septic Shock
  • Severe Sepsis
  • Mean Fluorescence Intensity
  • Causative Pathogen
  • Acute Pyelonephritis

Background

Septic syndrome is one of the leading causes of death. Its great lethality had led to several randomized trials of the administration of various types of immunotherapy. The concept of all these types of therapeutic approach was to modulate the exaggerated immune response of the host [1]. However most of results were disappointing. Several probable explanations for these failures have been given; among them the heterogeneity of patients is the most likely. This probably has to do with the type of underlying infection, the causative microorganism and the co-morbid conditions. In a recent prospective study of the Hellenic Sepsis Study Group http://www.sepsis.gr 505 patients were enrolled; changes of the innate and adaptive immunity were evaluated with immunophenotyping performed within the first 24 hours from diagnosis. Results showed that changes occurring during transition from sepsis to severe sepsis or septic shock differed in relation with the type of underlying infection [2].

Triggering receptor expressed on myeloid cells -1 (TREM-1) is a pattern-recognition receptor expressed on neutrophils and monocytes. It participates in innate immune responses and it is activated in the event of disseminated bacterial infections like sepsis. Expression of TREM-1 is up-regulated after stimulation with bacterial and fungal products. This leads to production of pro-inflammatory mediators, mainly of tumour necrosis factor-alpha and of interleukin-8. Although the exact ligand of TREM-1 remains unknown, it is believed that microbial molecules like endotoxins of the cell wall of Gram-negative bacteria and peptidoglycan of the cell wall of Gram-positive cocci may stimulate TREM-1 [3–9]. Missing identification of the exact ligand for TREM-1 creates the hypothesis that TREM-1 expression on neutrophils and monocytes in sepsis may differ according to the type of infection causing sepsis and/or the type of implicated bacteria.

Based on recent data for the crucial role of the type of the underlying infection in immune responses in sepsis [2], the purpose of the present study was to investigate the pattern of TREM-1 expression on cells of myeloid origin in a prospective cohort of sepsis in relation with the causative infection and the offending pathogen.

Methods

Study design

This is a prospective, multicentre clinical study conducted over the period June 2009-December 2009. None of the patients was enrolled in the studies already conducted and published by the Hellenic Sepsis Study Group [2, 10, 11]. The protocol was approved by the Ethics committees of all hospitals of the participating study sites. Written consent was provided from patients or their first-degree relatives for patients unable to consent.

Inclusion criteria were: a) age ≥ 18 years; b) sepsis due to either lower respiratory tract infection or acute pyelonephritis or intrabdominal infection or primary bacteremia/fungemia; and c) blood sampling within less than 24 hours from advent of signs of sepsis.

Exclusion criteria were: a) HIV infection and b) neutropenia defined as an absolute neutrophil count lower than 1000 neutrophils/mm3.

Patients were classified as uncomplicated sepsis and as severe sepsis and/or septic shock according to the criteria of the ACCP/SCCM [11, 12].

Acute infection of the lower respiratory tract was defined by all the following [13]: (1) physical signs compatible with a lower respiratory tract infection; and b) new pulmonary infiltrates on chest x-ray. It was divided into community-acquired pneumonia (CAP) if the patient had no history of contact with any hospital environment within the last 3 months; and hospital-acquired pneumonia (HAP) if either the patient had some contact with hospital environment within the last 3 months or infection was diagnosed more than 48 hours after hospital admission without being under incubation upon admission.

Ventilator-associated pneumonia (VAP) was HAP presented when a patient under intratracheal intubation and mechanical ventilation for ≥ 48 hours had all the following [14, 15]: a) core temperature > 38°C or < 36°C; b) purulent tracheobronchial secretions; and c) new pulmonary infiltrates on chest x-ray.

Acute pyelonephritis was defined for every patient with all the following [16]: a) core temperature > 38°C; b) radiological evidence consistent with the diagnosis; and c) ≥ 10 white blood cells in centrifuged urine sample or ≥ 2 + in urine stick for white blood cells and nitrite.

Acute intra-abdominal infection was defined for every patient with all the following [17] a) core temperature > 38°C; and b) radiological evidence (abdominal x-ray, abdominal ultrasound, abdominal or computed tomography) consistent with an acute abdominal infection.

Primary bacteremia or fungemia was defined for any patient with all the following [17]: a) peripheral blood culture positive for Gram-positive or Gram-negative bacteria or fungal species. Coagulase-negative Staphylococcus spp and skin commensals were considered contaminants unless isolated at least two times or isolated from both a peripheral vein and a central catheter and they had the same antibiograms; and b) absence of any primary site of infection after extensive patient work-out.

Patients' follow up

Seven ml of blood were sampled after venipuncture of one forearm vein under aseptic conditions; five ml were collected into a heparin-coated tube for flow cytometry; another two ml were collected into pyrogen-free tubes. Tubes were transported within one hour via a courier service to the central lab located at the 4th Department of Internal Medicine, ATTIKON General Hospital.

Enrolled patients were followed-up on a daily basis for a total of 28 days. APACHE II scores were calculated upon enrolment.

Flow cytometry

Red blood cells were lysed with ammonium chloride 1.0 mM. White blood cells were washed three times with PBS (pH. 7.2) (Merck, Darmstadt, Germany) and stained with the monoclonal antibody anti-TREM-1(R&D Systems, Minneapolis, USA) at the fluorochrome phycoerythrin (PE, emission 575 nm). The incubation took place at 4°C for 45 min in the dark. After reconstitution with 0.5 ml phosphate buffered saline pH: 7.2 cells were analyzed through the EPICS XL/MSL flow cytometer (Beckman Coulter Co, Miami, FL, USA) with gating for neutrophils and monocytes based on their characteristic forward and side scattering. IgG isotypic negative controls PE conjugated (IgG1) were applied before the start of analysis. Results were expressed as % of gated cells and as mean fluorescence intensity (MFI).

sTREM-1 measurements

Pyrogen-free tubes were centrifuged and serum was kept refrigerated at -70°C until assayed. Concentrations of soluble TREM-1 (sTREM-1) were measured in duplicate by an enzyme immunoassay (R&D Inc, Minneapolis, USA). The lower detection limit was 15.1 pg/ml.

Statistical analysis

Results were expressed as means ± SE. Comparisons of baseline qualitative characteristics were done by X2-test and of quantitative baseline characteristics by the Student's t-test. Comparisons of TREM-1 expression between patients at sepsis and patients at severe sepsis/shock with the same type of infection or pathogen were done by the Kruskall-Wallis test; those between different types of infections or pathogens separately for patients at sepsis and patients at severe sepsis/shock were done by the Mann-Whitney U test. Correlation between APACHE II score and TREM-1 expression was done according to Spearman's rank of order. P values below 0.05 after adjustment for multiple comparisons were considered significant.

Results

A total of 213 patients were enrolled in the study; 125 with sepsis and 88 with severe sepsis/shock. Their demographic and clinical characteristics are shown in Table 1. As expected, APACHE II scores and mortality were greater among patients with severe sepsis/shock.
Table 1

Demographic and clinical characteristics of patients enrolled in the study.

 

Sepsis

Severe sepsis/shock

p

Number

125

88

 

Male/Female

69/56

43/45

0.307

Age (years, mean ± SD)

62.5 ± 22.2

72.5 ± 13.1

< 0.0001

APACHE II score

11.52 ± 5.76

22.68 ± 8.50

< 0.0001

Type of infection (n)

  

p: 0.004

Acute pyelonephritis

56

18

 

Pneumonia (CAP)

16

20

 

Intra-abdominal Infection

30

20

 

Bacteremia

13

15

 

VAP/HAP

10

15

 

Predisposing Factors (n, %)

  

0.188

Chronic Renal Disease

15 (12.0)

12 (13.6)

 

Chronic Obstructive Pulmonary Disease

10 (8.0)

10 (11.4)

 

Heart Failure

9 (7.2)

17 (19.3)

 

Diabetes mellitus type 2

27 (21.6)

17 (19.3)

 

Solid tumor malignancy

5 (4.0)

7 (7.9)

 

Isolated pathogens irrespective of source (n, %)

  

0.037

Escherichia coli

21 (16.8)

4 (4.5)

 

Pseudomonas aeruginosa

7 (5.6)

5 (5.7)

 

Klebsiella pneumoniae

5 (4)

9 (10.2)

 

Acinetobacter baumannii

2 (1.6)

7 (7.9)

 

Other Gram-negatives

10 (8.0)

4 (4.5)

 

Staphylococcus aureus

2 (1.6)

2 (2.3)

 

Other Gram-positive

2 (1.6)

2 (2.3)

 

Death

10 (8.0)

49 (55.7)

< 0.0001

Expression of TREM-1 on the membrane of neutrophils and monocytes of the first day of patients with sepsis and severe sepsis/shock are shown in Figure 1. Among patients with intra-abdominal infection, expression of TREM -1 on neutrophils and monocytes, was significantly lower at severe sepsis/shock compared with sepsis (P = 0.009 for neutrophils, P = 0.022 for monocytes). That was also the case for TREM-1 expression on neutrophils among patients with VAP/HAP (P = 0.049 between severe sepsis/shock and sepsis).
Figure 1
Figure 1

Expression of TREM-1 on the first day of presentation of sepsis and of severe sepsis/septic shock on the surface of neutrophils and monocytes related with the causative type of infection. P values indicate statistically significant differences between sepsis and severe sepsis/shock at the specific infection.

When comparing patients at severe sepsis with patients at septic shock, it was found that expression of TREM-1 on neutrophils was further decreased in the event of septic shock within patients with intrabdominal infection (P = 0.049 compared with severe sepsis) and within patients with VAP/HAP (P = 0.009 compared with severe sepsis).

No significant correlation was found between expression of TREM-1 on neutrophils and monocytes and APACHE II score.

Gram-negative community-acquired bacteria were the most frequent isolated pathogens. Expression of TREM-1 on neutrophils of patients infected by the latter type of pathogens was significantly lower in severe sepsis/shock than in sepsis (P = 0.030) (Figure 2). No differences were found between severe sepsis and septic shock. When analysis involved only patients with sepsis, the MFI of TREM-1 on neutrophils of patients bearing infections by community-acquired Gram-negative bacteria was lower than the MFI of TREM-1 on neutrophils of patients bearing infections by hospital-acquired Gram-negative bacteria (P = 0.003 between them).
Figure 2
Figure 2

Expression of TREM-1 on the first day of presentation of sepsis and of severe sepsis/septic shock on the surface of neutrophils and monocytes in relation with the type of the pathogen. P values indicate statistically significant differences between sepsis and severe sepsis/shock at the specific type of pathogen.

Among the total patients where the causative pathogen was isolated, septic syndrome was of monomicrobial origin in 78 patients; in 20 patients septic syndrome was of polymicrobial origin. MFI of TREM-1 on the membrane of monocytes of patients bearing infections of monomicrobial origin at severe sepsis/shock was greater than of patients with infections of polymicrobial origin at severe sepsis/shock (P = 0.032) (Figure 3). No differences were found between severe sepsis and septic shock. However, analysis of the expression of TREM-1 within patients with sepsis found that it was significantly greater in patients with polymicrobial infections than in patients with monomicrobial infections (P = 0.040 regarding differences of % expression of TREM-1 on neutrophils; P = 0.008 regarding differences of MFI expression of TREM-1 on neutrophils).
Figure 3
Figure 3

Expression of TREM-1 on the first day of presentation of sepsis and of severe sepsis/septic shock on the surface of neutrophils and monocytes in relation with the presence of infection of polymicrobial or monomicrobial origin. P values indicate statistically significant differences between sepsis and severe sepsis/shock at the specific cause.

Differences similar to those found for the expression of TREM-1 between sepsis and severe sepsis/shock were not observed for sTREM-1 (Figure 4).
Figure 4
Figure 4

Serum concentrations of sTREM-1 on the first day of presentation of sepsis and of severe sepsis/septic shock in relation with the causative type of infection and with the implicated pathogen.

Discussion

TREM-1 is a receptor engaged on the cell membranes of neutrophils and of monocytes that is expressed during the septic syndrome upon stimulation with microbial products. Activation of TREM-1 leads to the transcription of genes of pro-inflammatory cytokines that play a pivotal role in the amplification of the immune response. During the septic process, surface TREM-1 expression on the cells of the innate immune system is highly modulated [18–20]. Expression of TREM-1 on the surface of circulating monocytes is increased in septic shock as evidenced in a previous study of 25 patients. Expression of TREM-1 was compared with patients with systemic inflammatory response syndrome of non-infectious origin and no data were available for patients at the stages of sepsis and of severe sepsis [21]. It seems that a circulating factor in the serum of shocked patients stimulates the expression of TREM-1 [22].

Much more evidence is available for the kinetics of the soluble counterpart of TREM-1 i.e. of sTREM-1. Concentrations are much greater in serum in the case of septic shock than in the cases of sepsis or of severe sepsis [22–24]. To this end, many authors propose that sTREM-1 may be used as a surrogate marker that helps diagnosis of critically ill patients with signs of systemic inflammatory response [25, 26].

The present study provides further insight in the modulation of TREM-1 expression in sepsis. Results suggest that TREM-1 expression on the membranes of neutrophils and monocytes in patients with septic syndrome is related to the type of infection. Expression is decreased within patients at severe sepsis who are suffering either from an intra-abdominal infection or from VAP/HAP compared with patients at sepsis suffering from similar infections. This is further decreased among patients at septic shock. Modulation of the immune status in sepsis by the underlying type of infection has also being shown in a recent publication of our group. Both innate and adaptive immune responses differed considerably between sepsis due to VAP and sepsis due to other types of infection. VAP was characterized by substantial decreases of CD4-lymphocytes and immunoparalysis of monocytes in contrast to other infections [27].

Modulation of the expression of TREM-1 was also affected by the type of microbial pathogen. More precisely, expression of TREM-1 was decreased when severe sepsis/shock developed in the field of infections caused by Gram-negative community-acquired bacteria.

Expression of TREM-1 on the membranes of monocytes is decreased in patients with severe sepsis/shock and polymicrobial infections compared to patients with sepsis. Explanations for these differences remain theoretical. The ligand of TREM-1 is not clearly defined. TREM-1 receptor is mainly expressed on neutrophils and monocytes after bacterial and fungal stimuli, so as to be considered one important counterpart of the innate immune response in sepsis [7, 8]. The presented data suggest that TREM-1 expression on neutrophils and monocytes is decreased upon transition from sepsis to severe sepsis/shock in a fashion depending on the underlying type of infection and on the causative pathogen. Since TREM-1 is a pro-inflammatory receptor, it may be hypothesized that the observed decrease of TREM-1 expression upon aggravation to severe sepsis/shock may be a component of the immunoparalysis taking place in sepsis. At the stage of immunoparalysis, monocytes of septic patients fail to produce a similar amount of cytokines as monocytes of the non-septic host do when stimulated ex vivo [2].

It is suggested that part of TREM-1 over-expressed on cell membranes is shed in the systemic circulation in a soluble form known as sTREM-1. sTREM-1 is considered to represent an anti-inflammatory response of the host [28]. In the present study, serum kinetics of sTREM-1 did not follow changes of the expression of TREM-1 suggesting that simple shedding of the membrane receptor did not take place.

Conclusions

The presented results show for the first time that expression of the TREM-1 receptor on the cell membranes of circulating neutrophils and monocytes early after diagnosis differs greatly between sepsis and severe sepsis/shock in relation; this is linked with the underlying infection and the causative pathogen. These results may have a major impact on therapeutics for the management of the septic patients.

Abbreviations

APACHE: 

acute physiology and chronic health evaluation

CAP: 

community-acquired pneumonia

COPD: 

chronic obstructive pulmonary disease

HAP: 

hospital-acquired pneumonia

LPS: 

lipopolysaccharide

MFI: 

mean fluorescence intensity

SE: 

standard error

sTREM-1: 

soluble Trigerring receptor expressed on myeloid cells-1

TREM-1: 

Triggering receptor expressed on myeloid cells-1

VAP: 

ventilator-associated pneumonia.

Declarations

Acknowledgements

The study was supported by the Hellenic Institute for the Study of Sepsis

Authors’ Affiliations

(1)
4th Department of Internal Medicine, University of Athens, Medical School, ATTIKON General Hospital, 1 Rimini Str, 12462 Athens, Greece
(2)
2nd Department of Critical Care, University of Athens, Medical School, ATTIKON General Hospital, 1 Rimini Str, 12462 Athens, Greece
(3)
1st Department of Internal Medicine, "Thriasion" Elefsina General Hospital, Leoforos Gennimata, 19600 Magoula, Greece
(4)
2nd Department of Urology, "Sismanogleion" Athens Hospital, 1 Sismanogleiou Str, 15126 Maroussi, Greece
(5)
Intensive Care Unit, "Ippokrateion" Athens General Hospital, 114 Vassilis Sofias Str, 11527 Athens, Greece
(6)
2nd Department of Surgery, University of Thessaloniki, Medical School, 41 Ethnikis Aminis Str, 54635 Thessaloniki, Greece
(7)
2nd Department of Internal Medicine, "Sismanogleion" Athens Hospital, 1 Sismanogleiou Str, 15126 Maroussi, Greece
(8)
Intensive Care Unit, "Laikon" Athens General Hospital, 17 Aghiou Thoma Str, 11527 Athens, Greece
(9)
Department of Plastic Surgery, 251 Air Force General Hospital, 3 Kanellopoulou Str, 112527 Athens, Greece
(10)
Intensive Care Unit, "Aghia Olga" Athens General Hospital, 3-5 Aghia Olga Str, 14233 Nea Ionia, Greece
(11)
3rd Department of Pulmonary Medicine, "Sismanoglion" Athens Hospital, 1 Sismanogleiou Str, 15126 Maroussi, Greece

References

  1. Vincent JL, Sun Q, Dubois MJ: Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis. 2002, 34: 1084-1093. 10.1086/339549.View ArticlePubMedGoogle Scholar
  2. Gogos C, Kotsaki A, Pelekanou A, Giannikopoulos G, Vaki I, Maravitsa P, Adamis S, Alexiou Z, Andrianopoulos G, Antonopoulou A, Athanasia S, Baziaka F, Charalambous A, Christodoulou S, Dimopoulou I, Floros I, Giannitsioti E, Gkanas P, Ioakeimidou A, Kanellakopoulou K, Karabela N, Karagianni V, Katsarolis I, Kontopithari G, Kopterides P, Koutelidakis I, Koutoukas P, Kranidioti H, Lignos M, Louis K, et al: Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Crit Care. 2010, 14: R96-10.1186/cc9031.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Bouchon A, Facchetti F, Welgant MA, Colonna M: TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature. 2001, 410: 1103-1107. 10.1038/35074114.View ArticlePubMedGoogle Scholar
  4. Colonna M, Facchetti F: TREM-1 (trigerring receptor expressed on myeloid cells): a new player in acute inflammatory responses. J Infect Dis. 2003, 187 (Suppl 2): 397-401.View ArticleGoogle Scholar
  5. Ford JW, McVicar DW: TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol. 2009, 21: 38-46. 10.1016/j.coi.2009.01.009.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Tessarz A, Cerwenka A: The TREM-1/DAP12 pathway. Immunoogy Letters. 2008, 116: 111-116. 10.1016/j.imlet.2007.11.021.View ArticleGoogle Scholar
  7. Sharif O, Knapp S: From expression to signaling: Roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunology. 2008, 213: 701-713.Google Scholar
  8. Klesney-Tait J, Turnbull IR, Cilonna M: The TREM receptor family and signal integration. Nat Immunol. 2006, 7: 1266-1273. 10.1038/ni1411.View ArticlePubMedGoogle Scholar
  9. Radsak MP, Salih HR, Rammensee HR, Schild H: Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: differential regulation of activation and survival. J Immunol. 2004, 172: 4956-4963.View ArticlePubMedGoogle Scholar
  10. Giamarellos-Bourboulis EJ, Tsangaris I, Kanni Th, Mouktaroudi M, Pantelidou I, Adamis G, Atmatzidis S, Chrisofos M, Evangelopoulou V, Frantzeskaki F, et al: Procalcitonin as an early indicator of outcome in sepsis: a prospective observational study. J Hosp Infect. 2011, 77: 58-63. 10.1016/j.jhin.2010.07.026.View ArticlePubMedGoogle Scholar
  11. Georgopoulou AP, Savva A, Giamarellos-Bourboulis EJ, Georgitsi M, Raftogiannis M, Antonakos N, et al: Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. J Crit Care. 2011, 26: 331.e1-331.e7.View ArticleGoogle Scholar
  12. Levy M, Fink M, Marshall J, Abraham E, Angus D, Cook D, Cohen J, Opal S, Vincent J, Ramsay G, SCCM/ESICM/ACCP/ATS/SIS: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition conference. Crit Care Med. 2003, 31: 1250-1256. 10.1097/01.CCM.0000050454.01978.3B.View ArticlePubMedGoogle Scholar
  13. Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbath S, Tamm M, Müller B: Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia. A randomized trial. Am J Resp Crit Care Med. 2006, 174: 84-93. 10.1164/rccm.200512-1922OC.View ArticlePubMedGoogle Scholar
  14. Chastre J, Fagon JY: Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002, 165: 867-903.View ArticlePubMedGoogle Scholar
  15. Vincent JL: Ventilator-associated pneumonia. J Hosp Infect. 2004, 57: 272-280. 10.1016/j.jhin.2003.06.001.View ArticlePubMedGoogle Scholar
  16. Pinson AG, Philbrick JT, Lindbeck GH, Schorling JB: Fever in the clinical diagnosis of acute pyelonephritis. Am J Emerg Med. 1997, 15: 148-151. 10.1016/S0735-6757(97)90087-5.View ArticlePubMedGoogle Scholar
  17. Calandra T, Cohen J: The international Sepsis Forum Consensus definitions of infections in the intensive care unit. Crit Care Med. 2005, 33: 1639-48.View ArticleGoogle Scholar
  18. Vincent JL: Clinical sepsis and septic shock definition, diagnosis and management principles. Langenbecks Arch Surg. 2008, 393: 817-824. 10.1007/s00423-008-0343-1.View ArticlePubMedGoogle Scholar
  19. Remick DJ: Pathophysiology of sepsis. Am J Pathol. 2007, 170: 1435-1444.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Bouchon A, Dietrich J, Colonna M: Cutting edge. Inflammatory responses can be trigerred by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol. 2000, 164: 4991-4995.View ArticlePubMedGoogle Scholar
  21. Gibot S, Le Renard PE, Bollaert PE, Kolopp-Sarda MN, Bene MC, Faure GC, Levy B: Surface trigerring receptor expressed on myeloid cells 1 expression patterns in septic shock. Intensive Care Med. 2005, 31: 594-597. 10.1007/s00134-005-2572-x.View ArticlePubMedGoogle Scholar
  22. Dimopoulou I, Orfanos SE, Pelekanou A, Kotanidou A, Livaditi O, Augustatou C, Zervou M, Douka E, Theodorakopoulou M, Karagianni V, Douzinas E, Armaganidis A, Giamarellos-Bourboulis EJ: Serum of patients with septic shock stimulates the expression of TREM-1 on U937 monocytes. Inflamm Res. 2009, 58: 127-132. 10.1007/s00011-008-7039-4.View ArticlePubMedGoogle Scholar
  23. Gibot S, Kolopp-Sarda MN, Béné MC, Cravoisy A, Levy B, Faure GC, Bollaert PE: Plasma level of a trigerring receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med. 2004, 141: 9-15.View ArticlePubMedGoogle Scholar
  24. Barati M, Bashar FR, Shahrami R, Zadeh MH, Taher MT, Nojomi M: Soluble triggering receptor expressed on myeloid cells 1 and the diagnosis of sepsis. J Crit Care. 2010, 25: 362.e1-e6. 10.1016/j.jcrc.2009.10.004.View ArticleGoogle Scholar
  25. Barraud D, Gibot S: Triggering receptor expressed on myeloid cells 1. Crit Care Clin. 2011, 27: 265-279. 10.1016/j.ccc.2010.12.006.View ArticlePubMedGoogle Scholar
  26. Porfiridis I, Plachouras D, Karagianni V, Kotanidou A, Papiris S, Giamarellou H, Giamarellos-Bourboulis EJ: Diagnostic value of triggering receptor expressed on myeloid cells-1 and C-reactive protein for patients with lung infiltrates: an observational study. BMC Infectious Diseases. 2010, 10: 286-10.1186/1471-2334-10-286.View ArticleGoogle Scholar
  27. Pelekanou A, Tsangaris I, Kotsaki A, Karagianni V, Giamarellou H, Armaganidis A, Giamarellos-Bourboulis EJ: Decrease of CD4-lymphocytes and apoptosis of CD14-monocytes are characteristic alterations in sepsis caused by ventilator-associated pneumonia: results from an observational study. Crit Care. 2009, 13: R172-10.1186/cc8148.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Giamarelos-Bourboulis EJ, Zakynthinos S, Baziaka F, Papadomichelakis E, Virtzili S, Koutoukas P, Armaganidis A, Giamarellou H, Roussos C: Soluble trigerring receptor expressed on myeloid cells-1 as an anti-inflammatory mediator in sepsis. Intensive Care Med. 2006, 32: 237-243. 10.1007/s00134-005-0017-1.View ArticleGoogle Scholar

    29. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/11/309/prepub

Copyright

© Poukoulidou et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

BMC Infectious Diseases

ISSN: 1471-2334

Contact us